KMG Fiduciary Partners LLC Makes New $209,000 Investment in Schrödinger, Inc. (NASDAQ:SDGR)

KMG Fiduciary Partners LLC bought a new stake in Schrödinger, Inc. (NASDAQ:SDGR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,530 shares of the company’s stock, valued at approximately $209,000.

Several other large investors have also recently bought and sold shares of the company. Brio Consultants LLC acquired a new stake in Schrödinger during the 4th quarter worth $391,000. Virtu Financial LLC grew its holdings in shares of Schrödinger by 148.2% in the 3rd quarter. Virtu Financial LLC now owns 18,114 shares of the company’s stock valued at $861,000 after buying an additional 10,816 shares during the period. Pentwater Capital Management LP grew its holdings in shares of Schrödinger by 146.7% in the 3rd quarter. Pentwater Capital Management LP now owns 37,000 shares of the company’s stock valued at $1,758,000 after buying an additional 22,000 shares during the period. Sei Investments Co. acquired a new position in shares of Schrödinger in the 3rd quarter valued at $264,000. Finally, Schonfeld Strategic Advisors LLC grew its holdings in shares of Schrödinger by 685.8% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 31,968 shares of the company’s stock valued at $1,520,000 after buying an additional 27,900 shares during the period. Institutional investors own 36.07% of the company’s stock.

Several brokerages have recently issued reports on SDGR. Jefferies Financial Group raised shares of Schrödinger from a “hold” rating to a “buy” rating and boosted their price target for the company from $70.00 to $75.00 in a report on Monday, October 12th. Bank of America raised shares of Schrödinger from a “neutral” rating to a “buy” rating and set a $74.00 price target for the company in a report on Monday, November 23rd. BidaskClub lowered shares of Schrödinger from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 30th. Finally, Morgan Stanley cut their price objective on shares of Schrödinger from $90.00 to $89.00 and set an “equal weight” rating on the stock in a research report on Friday, November 13th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $83.20.

In related news, major shareholder David E. Shaw sold 187,446 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $57.42, for a total transaction of $10,763,149.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Cony D’cruz sold 2,800 shares of the stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $85.30, for a total transaction of $238,840.00. Following the sale, the insider now owns 2,800 shares in the company, valued at approximately $238,840. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,892,963 shares of company stock worth $174,664,922.

SDGR opened at $88.50 on Thursday. Schrödinger, Inc. has a 12 month low of $25.50 and a 12 month high of $99.50. The firm’s fifty day simple moving average is $76.67 and its 200 day simple moving average is $67.43.

Schrödinger (NASDAQ:SDGR) last issued its earnings results on Thursday, November 12th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.07. The firm had revenue of $25.80 million during the quarter, compared to the consensus estimate of $23.51 million. The firm’s revenue for the quarter was up 29.0% on a year-over-year basis. As a group, equities analysts forecast that Schrödinger, Inc. will post -0.53 EPS for the current year.

Schrödinger Profile

Schrödinger, Inc provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.

Further Reading: Trading Stocks – What are percentage gainers?

Institutional Ownership by Quarter for Schrödinger (NASDAQ:SDGR)

Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.